Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex.
Nat Cancer
; 3(10): 1211-1227, 2022 10.
Article
in En
| MEDLINE
| ID: mdl-36253486
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Cyclin-Dependent Kinase 9
/
Anaplastic Lymphoma Kinase
/
Antineoplastic Agents
Type of study:
Prognostic_studies
Limits:
Animals
/
Female
/
Humans
Country/Region as subject:
America do norte
Language:
En
Journal:
Nat Cancer
Year:
2022
Document type:
Article
Affiliation country:
Estados Unidos
Country of publication:
Reino Unido